Gilead Sciences Inc. (GILD)
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors
Gilead Sciences (GILD) closed the most recent trading day at $76.49, moving +0.57% from the previous trading session.
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
A Look At Gilead Sciences After Its Recent Weakness
Gilead Sciences has dropped 15% YTD, impacted by disappointing trial results from Trodelvy after acquiring Immunomedics for over $20 billion. Despite challenges, the company had a financially strong 1Q 2024, with growth in non-Veklury product sales and a strong HIV business. Gilead Sciences has an impressive R&D arm and strong financial performance, with a focus on building a balanced portfolio for long-term shareholder returns.
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Pfizer is busy growing income streams to replace its big COVID-related revenue from years past. Paycom is profitably helping companies help themselves with self-service software.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Gilead Sciences (GILD) reachead $72.41 at the closing of the latest trading day, reflecting a -0.21% change compared to its last close.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Dividend stocks can deliver both reliable income and substantial capital appreciation over long periods of time. Investing $51,000 across these three dividend-paying options could yield about $3,000 in yearly income.
